DIVAn ethnography about the work of genome scientists, entrepreneurs, and policy makers in biotech drug development in the United States and India./div

The juxtaposition of biopolitical critique and animal studies--two subjects seldom theorized together--signals the double-edged intervention of Animal Capital. Nicole Shukin pursues a resolutely materialist engagement with the "question of the animal," challenging the philosophical idealism that has dogged the question by tracing how the politics of capital and of animal life impinge on one another in market cultures of the twentieth and early twenty-first centuries.

Focusing on the period between the 1970s and the present, Life as Surplus is a pointed and important study of the relationship between politics, economics, science, and cultural values in the United States today. Melinda Cooper demonstrates that the history of biotechnology cannot be understood without taking into account the simultaneous rise of neoliberalism as a political force and an economic policy. From the development of recombinant DNA technology in the 1970s to the second Bush administration's policies on stem cell research, Cooper connects the utopian polemic of free-market capitalism with growing internal contradictions of the commercialized life sciences. The biotech revolution relocated economic production at the genetic, microbial, and cellular level. Taking as her point of departure the assumption that life has been drawn into the circuits of value creation, Cooper underscores the relations between scientific, economic, political, and social practices. In penetrating analyses of Reagan-era science policy, the militarization of the life sciences, HIV politics, pharmaceutical imperialism, tissue engineering, stem cell science, and the pro-life movement, the author examines the speculative impulses that have animated the growth of the bioeconomy. At the very core of the new post-industrial economy is the transformation of biological life into surplus value. Life as Surplus offers a clear assessment of both the transformative, therapeutic dimensions of the contemporary life sciences and the violence, obligation, and debt servitude crystallizing around the emerging bioeconomy.

From call centers, overseas domestic labor, and customer care to human organ selling, gestational surrogacy, and knowledge work, such as software programming, life itself is channeled across the globe from one population to another. In Life Support, Kalindi Vora demonstrates how biological bodies have become a new kind of global biocapital. Vora examines how forms of labor serve to support life in the United States at the expense of the lives of people in India. She exposes the ways in which even seemingly inalienable aspects of human life such as care, love, and trust—as well as biological bodies and organs—are not only commodifiable entities but also components essential to contemporary capitalism. As with earlier modes of accumulation, this new global economy has come to rely on the reproduction of life for expansion. Human bodies and subjects are playing a role similar to that of land and natural resource dispossession in the period of capitalist growth during European territorial colonialism. Indeed, the rapid pace at which scientific knowledge of biology and genetics has accelerated has opened up the human body as an extended site for annexation, harvest, dispossession, and production.

This collection of anthropology of science essays explores the new forms of capital, markets, ethical, legal, and intellectual property concerns associated with new forms of research in the life sciences.

Continuing his pioneering theoretical explorations into the relationships among biosciences, the market, and political economy, Kaushik Sunder Rajan introduces the concept of pharmocracy to explain the structure and operation of the global hegemony of the multinational pharmaceutical industry. He reveals pharmocracy's logic in two case studies from contemporary India: the controversial introduction of an HPV vaccine in 2010, and the Indian Patent Office's denial of a patent for an anticancer drug in 2006 and ensuing legal battles. In each instance health was appropriated by capital and transformed from an embodied state of well-being into an abstract category made subject to capital's interests. These cases demonstrate the precarious situation in which pharmocracy places democracy, as India's accommodation of global pharmaceutical regulatory frameworks pits the interests of its citizens against those of international capital. Sunder Rajan's insights into this dynamic make clear the high stakes of pharmocracy's intersection with health, politics, and democracy.

This book explores the promissory discourses and practices associated with the bioeconomy, focusing especially on the transformation of institutions; the creation, appropriation, and distribution of value; the struggle over resources, power, and meaning; and the role of altruism, kinship, and care practices. Governments and science enthusiasts worldwide are embracing the bioeconomy, championing it as the key to health, wealth, and sustainability, while citing it as justification to transform research and regulatory institutions, health and agricultural practices, ethics of privacy and ownership, and conceptions of self and kin. Drawing together studies from Asia, Australia, the Americas, and Europe, this volume encompasses subjects as diverse as regenerative medicine, population health research, agricultural finance, biobanking, assisted reproduction, immigration, breastfeeding, self-help groups, GM fish, and mining sewage.